Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
May 09, 2024 16:05 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces First Quarter 2024 Financial Results
May 08, 2024 16:05 ET
|
Supernus Pharmaceuticals, Inc.
Net sales of Qelbree® increased 75% to $45.1 million compared to first quarter 2023.Total revenues were $143.6 million. Total revenues excluding Trokendi XR® and Oxtellar XR® net product sales...
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
May 01, 2024 08:00 ET
|
Supernus Pharmaceuticals, Inc.
Busy is getting candid about navigating her ADHD diagnosis and treatment experience with Qelbree®The percentage of women newly diagnosed with ADHD between 23-29 and 30-49 years of age nearly doubled...
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
April 24, 2024 16:05 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Provides Regulatory Update for SPN-830
April 08, 2024 08:00 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Participate in Two Upcoming Investor Conferences
March 06, 2024 16:30 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
February 28, 2024 16:30 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024 16:05 ET
|
Supernus Pharmaceuticals, Inc.
Fourth quarter 2023 net sales of Qelbree® increased 97% to $46.4 million compared to fourth quarter 2022; Full year 2023 net sales of Qelbree increased 129% to $140.2 million compared to full year...
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
February 13, 2024 16:05 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
February 05, 2024 08:30 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...